2,526 research outputs found

    PTRM 380.R01: Recreation Administration and Leadership

    Get PDF

    Michigan\u27s Teacher Certification Requirement as Applied to Religiously Motivated Home Schools

    Get PDF
    This Note defends the thesis that the teacher-certification requirement of Michigan\u27s compulsory attendance statute is unconstitutional as applied to people who, for sincere religious reasons, believe they must teach their children at home. Michigan courts have incorrectly applied a rational-basis test in regulating religiously motivated home schools, rather than the strict scrutiny required by the U.S. Supreme Court for cases involving both the free exercise of religion and parents\u27 interest in directing their children\u27s education

    Results from the Apollo passive seismic experiment

    Get PDF
    Recent results from the Apollo seismic network suggest that primitive differentiation occurred in the outer shell of the moon to a depth of approximately 300 km; and the central region of the moon is presently molten to a radius of between 200 and 300 km. If early melting to a depth of 300 to 400 km was a consequence of accretional energy, very short accretion times are required. The best model for the zone of original differentiation appears to be a crust 40 to 80 km thick, ranging in composition from anorthositic gabbro to gabbro; overlying an ultramafic cumulate (olivine-pyroxene) about 250 km thick. The best candidate for the molten core appears to be iron or iron sulphide. A new class of seismic signals has recently been identified that may correspond to shallow moonquakes. These are rare, but much more energetic than the more numerous, deep moonquakes

    Results from the Apollo passive seismic experiment

    Get PDF
    Recent results from the Apollo Seismic Network suggest that primitive differentiation occurred in the outer shell of the moon to a depth of approximately 300 km and the central region of the moon is presently molten to a radius of between 200 and 300 km. If early melting to a depth of 300 to 400 km was a consequence of accretional energy, very short accretion times are required. It was shown that the best model for the zone of original differentiation is a crust 40 to 80 km thick, ranging in composition from anorthositic gabbro to gabbro, and overlying an ultramafic cumulate about 250 km thick. The best candidate for the molten core appears to be iron or iron sulphide. A new class of seismic signals recently were identified that may correspond to shallow moonquakes. These are rare, but much more energetic than the more numerous, deep moonquakes

    Particle Acceleration by Fast Modes in Solar Flares

    Full text link
    We address the problem of particle acceleration in solar flares by fast modes which may be excited during the reconnection and undergo cascade and are subjected to damping. We extend the calculations beyond quasilinear approximation and compare the acceleration and scattering by transit time damping and gyroresonance interactions. We find that the acceleration is dominated by the so called transit time damping mechanism. We estimate the total energy transferred into particles, and show that our approach provides sufficiently accurate results We compare this rate with energy loss rate. Scattering by fast modes appears to be sufficient to prevent the protons from escaping the system during the acceleration. Confinement of electrons, on the other hand, requires the existence of plasma waves. Electrons can be accelerated to GeV energies through the process described here for solar flare conditions.Comment: 7 pages, 4 figures, accepted to Ap

    The SPAN cookbook: A practical guide to accessing SPAN

    Get PDF
    This is a manual for remote users who wish to send electronic mail messages from the Space Physics Analysis Network (SPAN) to scientific colleagues on other computer networks and vice versa. In several instances more than one gateway has been included for the same network. Users are provided with an introduction to each network listed with helpful details about accessing the system and mail syntax examples. Also included is information on file transfers, remote logins, and help telephone numbers

    Budget impact of adding ivabradine to standard of care in patients with chronic systolic heart failure in the United States

    Get PDF
    BACKGROUND: Heart failure (HF) costs 21billionannuallyindirecthealthcarecosts,80OBJECTIVE:ToestimatethebudgetimpactofivabradinefromaU.S.commercialpayerperspective.METHODS:Abudgetimpactmodelestimatedthepermemberpermonth(PMPM)impactofintroducingivabradinetoexistingformulariesbycomparingareferencescenario(SoC)andanewdrugscenario(ivabradine+SoC)inhypothetical1millionmembercommercialandMedicareAdvantageplans.Inbothscenarios,U.S.claimsdatawereusedforthereferencecumulativeannualratesofhospitalizations(HF,nonHFcardiovascular[CV],andnonCV),andhospitalizationrateswereadjustedusingSHIFTdata.ThemodelcontrolledformortalityriskusingSHIFTandU.S.lifetabledata,andhospitalizationcostswereobtainedfromU.S.claimsdata:HFrelated=21 billion annually in direct health care costs, 80% of which is directly attributable to hospitalizations. The SHIFT clinical study demonstrated that ivabradine plus standard of care (SoC) reduced HF-related and all-cause hospitalizations compared with SoC alone. OBJECTIVE: To estimate the budget impact of ivabradine from a U.S. commercial payer perspective. METHODS: A budget impact model estimated the per-member-per month (PMPM) impact of introducing ivabradine to existing formularies by comparing a reference scenario (SoC) and a new drug scenario (ivabradine + SoC) in hypothetical 1 million-member commercial and Medicare Advantage plans. In both scenarios, U.S. claims data were used for the reference cumulative annual rates of hospitalizations (HF, non-HF cardiovascular [CV], and non-CV), and hospitalization rates were adjusted using SHIFT data. The model controlled for mortality risk using SHIFT and U.S. life table data, and hospitalization costs were obtained from U.S. claims data: HF-related = 37,507; non-HF CV = 28,951;andnonCV=28,951; and non-CV = 17,904. The annualized wholesale acquisition cost of ivabradine was 4,500,withbaselineuseforthisnewdrugat2RESULTS:BasedontheapprovedU.S.indication,approximately2,000commerciallyinsuredpatientsfroma1millionmembercommercialplanwereeligibletoreceiveivabradine.IvabradineresultedinaPMPMcostsavingsof4,500, with baseline use for this new drug at 2%, increasing 2% per year. RESULTS: Based on the approved U.S. indication, approximately 2,000 commercially insured patients from a 1 million-member commercial plan were eligible to receive ivabradine. Ivabradine resulted in a PMPM cost savings of 0.01 and 0.04inyears1and3ofthecoremodel,respectively.Afterincludingtheacquisitionpriceforivabradine,themodelshowedadecreaseintotalcostsinthecommercial(0.04 in years 1 and 3 of the core model, respectively. After including the acquisition price for ivabradine, the model showed a decrease in total costs in the commercial (991,256 and 474,499,respectively)andMedicarepopulations(474,499, respectively) and Medicare populations (13,849,262 and 4,280,291,respectively)inyear1.Thisdecreasewasdrivenbyivabradinesreductioninhospitalizationrates.Forthecoremodel,theestimatedpharmacyonlyPMPMinyear1was4,280,291, respectively) in year 1. This decrease was driven by ivabradine’s reduction in hospitalization rates. For the core model, the estimated pharmacy-only PMPM in year 1 was 0.01 for the commercial population and $0.24 for the Medicare Advantage population. CONCLUSIONS: Adding ivabradine to SoC led to lower average annual treatment costs. The negative PMPM budget impact indicates that ivabradine is an affordable option for U.S. payers

    Adjustment of the Summer Marine Boundary Layer around Point Sur, California

    Get PDF

    Update on a Pharmacokinetic-Centric Alternative Tier II Program for MMT—Part I: Program Implementation and Lessons Learned

    Get PDF
    Concerns have been raised regarding environmental manganese exposure since high exposures have been associated with neurological disorders. The USA Environmental Protection Agency most recent human health risk assessment of inhaled manganese conducted in 1993 identified specific areas of uncertainty regarding manganese pharmacokinetics. This led to the development of a test rule under the USA Clean Air Act that required the generation of pharmacokinetic information on the inorganic manganese combustion products of the organometallic fuel additive methylcyclopentadienyl manganese tricarbonyl (MMT). The Alternative Tier 2 testing program for MMT, described in this paper, has yielded substantial pharmacokinetic data and has enabled the generation of physiologically based pharmacokinetic (PBPK) models for manganese. These models are capable of predicting tissue manganese concentrations across a variety of dose routes, levels, and durations while accounting for factors such as age, gender, and reproductive status, enabling the consideration of tissue dosimetry in future risk assessments
    corecore